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The Importance of the Level of
Maternal Anti-Ro/SSA Antibodies as
a Prognostic Marker of the Development
of Cardiac Neonatal Lupus Erythematosus
A Prospective Study of 186 Antibody-Exposed Fetuses and Infants
Edgar Jaeggi, MD,*§ Carl Laskin, MD,† Robert Hamilton, MD,*§ John Kingdom, MD,†
Earl Silverman, MD†‡
Toronto, Ontario, Canada
Objectives The purpose of this study was to determine whether cardiac complications of neonatal lupus erythematosus
(NLE) are related to maternal anti-Ro and anti-La autoantibody-levels.
Background Autoantibody-positive mothers are frequently referred for serial echocardiography because of the elevated fetal risk of
developing immune-mediated heart block. Little is known why only some and not all offspring are affected.
Methods All cases referred since 2000 for serial fetal echocardiography or cardiac complications related to maternal anti-
bodies were included. Patients without cardiac NLE (group 1) and with cardiac NLE (group 2) were compared.
Antibody levels were measured by enzyme-linked immunosorbent assay with a cutoff value of 8 U/ml for a posi-
tive test result.
Results Group 1 included 146 serially screened fetuses with normal pregnancy outcomes. Group 2 consisted of 40
fetuses/neonates with a diagnosis of heart block or endocardial fibroelastosis or both, and included 4 fetuses
diagnosed during serial screening. All cardiac complications were associated with moderate (50 U/ml; 15%) or
high (100 U/ml; 85%) maternal anti-Ro levels, independently of anti-La antibody titres. The event rate of com-
plete heart block was 5% for prospectively screened fetuses with Ro-values 50 U/ml (odds ratio: 7.8) and 0%
for fetuses with lower titres (p  0.0001). Infants with pre-natal exposure to high-titre anti-La levels 100 U/ml
were the most likely to have noncardiac features of NLE (event rate: 57%; odds ratio: 4.7).
Conclusions Our findings support that the amount of maternal antibodies, rather than their presence, is associated with fetal
tissue injury. As anti-Ro levels correlate with the risk of cardiac complications, serial echocardiography should be
limited to women with high anti-Ro-titres. (J Am Coll Cardiol 2010;55:2778–84) © 2010 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.02.042s
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asolated congenital complete atrioventricular block (CAVB)
as been recognized as a distinct clinical entity for 100 years.
t was only in the 1950s that it was recognized that maternal
utoantibodies will cross the placenta and that fetuses of
others with an autoimmune disease may develop CAVB
1,2). It took another 20 years before this association
ecame well recognized (3–5) and until the early 1980s that
rom the Divisions of *Cardiology and †Rheumatology, Departments of Pediatrics
nd Immunology, The Hospital for Sick Children, Toronto, Ontario, Canada; ‡The
ospital for Sick Children Research Institute, Toronto, Ontario, Canada; and the
Departments of Medicine and Obstetrics and Gynecology, Mount Sinai Hospital,
niversity of Toronto, Toronto, Ontario, Canada. Dr. Silverman is on the advisory
oard of Abbott Canada and Amgen/Wyeth Canada.i
Manuscript received October 15, 2009; revised manuscript received January 19,
010, accepted February 15, 2010.tudies documented a close association between maternal
nti-Ro/SSA and anti-La/SSB antibodies and congenital
eart block (6,7). It was subsequently shown that the
ighest relative risks of CAVB were seen in offspring of
others with antibodies against 52-kD Ro and 48-kD La
roteins (8,9).
The current hypothesis is that maternal antibodies with
pecificities to the Ro-particle cross the placenta and likely
nitiate the inflammation of the atrioventricular (AV) node
nd the myocardium in the susceptible fetus. Subsequent
eplacement of inflamed tissue with fibrosis will lead to
eart block, myocardial dysfunction, and/or endocardial
broelastosis (EFE) (10,11). The most common time of
ntibody-mediated fetal cardiac manifestations to be
nitially detected is between 20 and 24 gestational weeks
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June 15, 2010:2778–84 Fetal Heart Block and Maternal Antibodies12). Other manifestations of the so-called neonatal lupus
rythematosus syndrome (NLE) are frequently observed after
irth and include cutaneous rash, thrombocytopenia, leuko-
enia, anemia, and liver dysfunction (13). Unlike CAVB,
he noncardiac symptoms of NLE usually resolve within a
ew months after birth, coincident with the clearance of the
aternal antibodies from the child’s circulation.
It is unclear why NLE develops in only some but not all
ntibody-exposed fetuses. In prospectively examined preg-
ancies of mothers with anti-Ro and anti-La antibodies, the
eported prevalence of fetal CAVB is 1% to 5%, which rises
o 6% to 25% for those with a previously affected child with
eart block (14–17). Because of the fetal risk of acquiring
otentially life-threatening, irreversible heart disease and
he perception that this may be preventable if detected and
reated at an early stage of AV nodal disease, it is recom-
ended that antibody-positive mothers should be referred
or close fetal echocardiographic surveillance beginning in
he early second trimester (18–20).
The aim of this study was to determine if maternal
nti-Ro and -La antibody levels rather than their presence
ould be used to more accurately predict fetuses at risk of
mmune-mediated cardiac complications.
ethods
he Hospital for Sick Children provides the exclusive
ertiary cardiac care for approximately 80,000 live births per
ear. That includes the only program offering serial fetal
chocardiography for women with anti-Ro/-La antibodies
n our catchment area. The institutional research ethics
oard approved this prospective observational single center
tudy.
atient population. The study cohorts consisted of 186
ases exposed to maternal anti-Ro and -La antibodies
eferred either: 1) with a diagnosis of immune-mediated
ardiac complications (symptomatic cohort; n  40); or
) for serial echocardiography with a normal pregnancy
utcome (asymptomatic cohort; n  146) between January
000 and December 2008. The presence of these antibodies
as confirmed in a commercial and/or institutional labora-
ory before the referral for serial screening. Antibody-levels
ere determined in our laboratory at the time of referral
nd, when possible, in live-born infants by solid-phase
nzyme-linked immunosorbent assay (ELISA) using re-
ombinant human 60-kD Ro, 52-kD Ro, and 48-kD La
roteins (Phadia GmbH, Freiburg, Germany). The cutoff
or a positive test was 8 U/ml. Antibody levels were graded
s negative (8 U/ml), low positive (8 to 49 U/ml),
oderate positive (50 to 99 U/ml), and high positive (100
/ml). Our ELISA test did not allow the quantification of
itres 100 U/ml.
ohort with cardiac NLE. Heart block, myocardial dys-
unction, pericardial effusion, and EFE were considered as
ardiac manifestations of NLE. We prospectively collected
he clinical and outcome data of 39 mothers and their 40 Effspring with a fetal (n  34) or
eonatal (n  6) diagnosis of
mmune-mediated heart disease.
hey included 4 fetal cases with
primary referral for serial echo-
ardiographic surveillance with a
iagnosis of first-degree (n  1)
r third-degree (n  3) AV
lock.
ohort without cardiac NLE.
his cohort consisted of 125
others with 146 prospectively
valuated fetuses with a normal
regnancy outcome. Mothers
ere mainly referred on the basis of a diagnosed connective
issue disease (81%), a previous child with CAVB (6%), or
he presence of autoantibodies in an otherwise healthy
oman (13%). Mothers with no pregnancy history of
ardiac NLE were invited to undergo weekly fetal echocar-
iograms between 19 and 24 weeks. If a previous child had
AVB, we recommended 1- to 2-weekly echocardiograms
ntil 32 weeks. Informed consent was obtained before
nrollment. Our protocol also called for post-natal
ollow-up examinations of the child by a rheumatologist
E.S.) beginning at 4 to 6 weeks of age. This included
hysical examinations, a 12-lead electrocardiogram, and
erological, hematological, and biochemistry tests. Post-
atal examinations and electrocardiograms were obtained in
11 and 116 cases, respectively, within the recommended
ime frame. The findings were compared with the age-
atched normal values.
maging methods. Echocardiography with Philips iU22/
E33 (Philips ATL, Bothwell, Washington) and GE
ivid-7 (GE Medical Systems, Horten, Norway) ultra-
ound systems entailed 2-dimensional, Doppler, and
-mode imaging to detect cardiovascular abnormalities.
ollected data included atrial and ventricular rates, and in
ases with 1:1 AV conduction, the Doppler-derived AV
urations (21). Ventricular contractility was assessed quan-
itatively by M-mode echocardiography and after birth by
eft ventricular ejection fraction.
tudy definitions and treatment. Abnormalities were
lassified as bradycardia (fetal heart rate 120 beats/min),
V block, reduced fractional shortening 28%, EFE,
nd/or effusions in body cavities. First-degree AV block was
efined as persistent PR prolongation 2 z-scores above
he age-specific normal mean values (21,22). CAVB implies
omplete absence of electrical AV conduction. The EFE
as identified by echocardiography as areas of increased
rightness of endocardial surfaces, and if possible, con-
rmed by necropsy (23). It was graded as severe if there was
xtensive ventricular involvement.
Transplacental anti-inflammatory treatment as per our
nstitutional protocol (23) was used if 1 of the following was
etected: CAVB, reduced contractility, EFE, or effusions. If
Abbreviations
and Acronyms
AV  atrioventricular
CAVB  complete
atrioventricular block
EFE  endocardial
fibroelastosis
ELISA  enzyme-linked
immunosorbent assay
NLE  neonatal lupus
erythematosus
OR  odds ratioFE was detected, intravenous immunoglobulin (IVIG)
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Fetal Heart Block and Maternal Antibodies June 15, 2010:2778–84as also given to the mother (70 g every 2 to 3 weeks to
elivery) and to the newborn (single dose of 2 g/kg).
tatistics. Results are expressed as median (range), mean
D, or frequencies, as appropriate. Comparisons between
roups were performed with the chi-square test for categor-
cal variables and the Student t test for continuous variables.
he odds of NLE were calculated in the cohort of prospec-
ively examined fetuses with different levels of antibody
xposure. Statistical analyses were performed with Prism 5
GraphPad Software, San Diego, California).
esults
o determine the role of maternal antibody specificity in
LE, we compared the cohorts with and without cardiac
omplications (Table 1). All mothers in this study had
etectable anti-Ro antibodies, and approximately one-third
f them also had anti-La antibodies. Mothers with a normal
regnancy outcomes were mainly referred by their rheuma-
ologist for serial echocardiography. When we examined
aternal health, as may be expected, mothers of children
ith cardiac involvement were less likely to have had a
onnective tissue disease than were mothers of children
ithout cardiac involvement (15% vs. 81%; p  0.0001).
linical features of the cohort with cardiac NLE. Table 2
hows the characteristics, management, and outcome of 40
onsecutive cases with a fetal diagnosis (n  34; cases 1 to
4) or a neonatal diagnosis (n 6; cases 35 to 40) of cardiac
LE. Cases 1 to 4 were part of a prospective study and had
nitially been referred for serial fetal echocardiography in a
other known to have anti-Ro antibodies before the detec-
ion of heart block. Abnormalities were first diagnosed
n-utero at a median of 22.5 (18 to 37) gestational weeks or
mmediately after the delivery. Heart block was present in
7 of 40 (93%) cases, and the other 3 had either isolated
Characteristics of the 2 Patient Cohorts With (YAntibody-Related Cardiac SymptomsTable 1 Charact r stics of he 2 Patien CoAntibody-Related Cardiac Symptom
Antibody-Related Cardiac Symptoms
Maternal characteristics
Connective tissue disease
Median maternal age (range) 32
Number of pregnancies (offspring) 3
Primigravid
Previous live births 2
Previous child with heart block
Positive antibody tests 3
Cases with plasma level measurements 3
Negative anti-Ro, 8 U/ml
Low positive anti-Ro, 8–49 U/ml
Moderate positive anti-Ro, 50–99 U/ml
High positive anti-Ro, 100 U/ml 3
Negative anti-La, 8 U/ml 2
Low positive anti-La, 8–49 U/ml
Moderate positive anti-La, 50–99 U/ml
High positive anti-La, 100 U/mlericardial effusion (case 21), EFE (case 23), or EFE with
ydrops (case 31). Of 37 cases with heart block, it was
omplete in 35 cases, first degree in 2 cases, and associated
ith EFE in 10 cases. All 39 mothers had anti-Ro antibody
evels 50 U/ml, but only 6 had connective tissue disease,
nd 1 woman had a previous child with CAVB. Interest-
ngly, of 8 fetuses/infants with both anti-Ro and anti-La
ntibody levels 50 U/ml, none had EFE, fetal hydrops,
educed ventricular function, and/or died, whereas that was
he case in 12 (38%) of 32 cases with exposure only to high
nti-Ro levels (p  0.08).
Six of the 34 pre-natally detected cases did not receive
ntrauterine treatment because the referral occurred late
n gestation (case 12), the fetus had died (case 31),
reatment was declined (case 28), the pregnancy was
erminated (cases 2 and 10), or mild first-degree AV
lock was present and did not progress (case 4). The
ther 28 pregnancies were treated, including 3 cases with
ardiac disease other than CAVB. Case 21 received
orticosteroids as a result of treatment for its twin (case
0): the coincidental finding of pericardial effusion re-
olved within a week of treatment, whereas CAVB
ersisted in the sibling. Case 22 presented with bright
reas in both ventricles that almost completely resolved
ith transplacental treatment. Case 23 had diffuse EFE
f all papillary muscles, reduced biventricular contractil-
ty, and first-degree AV block with a significantly pro-
onged AV interval of 250 ms (z-score 14) by superior
ena cava/aorta pulse-wave Doppler. On treatment, the
ardiac function normalized within 1 week, the EFE
mproved, and the neonatal electrocardiogram confirmed
rst-degree AV block with a PR duration of 250 ms. Six
regnancies were referred perinatally and did not receive
ransplacental treatment (cases 35 to 40).
nd Without (No)With (Yes) and Without (No)
s No p Value
125
) 101 (81%) 0.0001
4–40.3) 33 (17.7–43.9) NS
144 (146)
) 54 (38%) NS
) 67 (47%) 0.01
) 8 (6%) NS
%) 144 (100%) NS
%) 129 (90%)
) 0 (0%) NS
) 73 (57%) 0.0001
) 6 (5%) NS
) 50 (39%) 0.0001
) 83 (64%) NS
) 14 (11%) NS
) 5 (4%) NS
) 27 (21%) NSes) ahorts
s
Ye
39
6 (15%
.3 (21.
9 (40)
8 (21%
8 (72%
1 (3%
9 (100
9 (100
0 (0%
0 (0%
6 (15%
3 (85%
6 (67%
5 (13%
1 (3%
7 (18%
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June 15, 2010:2778–84 Fetal Heart Block and Maternal Antibodiesutcome of the cohort without cardiac NLE. A median
f 4 (2–12) echocardiograms were performed in 146
symptomatic fetuses between 19 weeks (17 to 23 weeks)
nd 24 weeks (23 to 35 weeks). None experienced AV
lock, bradycardia, valvar regurgitation, EFE, cardiac
ysfunction, and/or body effusions during the observation
eriod. Electrocardiograms were obtained in 116 cases at
2 days (5 to 232 days) of life, showing sinus rhythm
153  16 beats/min) with normal AV conduction (97 
0 ms). Seventeen (15%) had transient QTc prolongation
haracteristics, Management, and Outcome of 40 Cases With Carttribu d to Presence of Mater al Anti-Ro AntibodiesTable 2 Characteristics, M gement, and Outcome of 40 sAttributed to Presence of Maternal Anti-Ro Antibodies
Case #
GA,*
Weeks
Anti-Ro,
U/ml
Anti-La,
Un/ml
AV Block,
Degree
Atrial Rate
<120 Beats/Min
Ven
<5
1 21 100 3 3
2 20 81 8 3
3 28 100 0 3
4 22 55 0 1
5 25 100 5 3
6 31 100 0 3
7 19 100 25 3
8 20 100 5 3
9 25 100 3 3
10 25 100 0 3
11 28 100 100 3
12 37 60 0 3
13 21 100 0 3
14 24 100 0 3
15 21 100 0 3
16 21 100 0 3
17 20 50 0 3
18 33 100 36 3
19 23 100 100 3
20 22 100 0 3
21 22 100 0 0
22 24 100 0 0
23 23 100 0 1
24 21 100 0 3
25 23 100 100 3
26 21 100 0 3
27 19 100 6 3 
28 26 100 0 3 
29 24 100 0 3
30 22 100 37 3
31 18 100 18 0 
32 20 100 100 3
33 23.5 100 100 3
34 25 100 0 3
35 39 70 2 3
36 34.5 100 100 3
37 35 100 0 3
38 39 80 12 3
39 31.1 100 74 3
40 36 100 100 3
Gestational age (GA) at anomaly diagnosis. Endocardial fibroelastosis (EFE):   present; 0  a
resent; 0  absent.
AV  atrioventricular; IUD  intrauterine death; IVIG  intravenous immune globulin; TOP  pretween 440 and 470 ms. None was treated with a beta-blocker, and no sudden infant death syndrome
ccurred. Of 30 children with no post-natal examinations
t our center, all had normal heart rates at birth and are
eportedly healthy according to their physicians. That
ikely precludes major undetected cardiac complications.
post-natal rheumatology evaluation was obtained for
11 infants, and 30 (27%) had transient hematological
bnormalities (n  14; 13%), abnormal liver function
ests (n  4; 4%), and/or a skin rash (n  17; 15%).
able 3 shows the relationship between maternal anti-
nomaliesith C rdiac Anomalies
ar Rate
ts/Min EFE
Hydrops/
(Effusion)
Reduced
Function Pre-Natal Therapy
Survival,
1 Yr
() Steroids, IVIG 
() No TOP
Steroids 
No 
() Steroids 
Steroids, salbutamol 
Steroids 
Steroids 
Steroids 
 () No TOP
Steroids, salbutamol 
No 
Steroids, salbutamol 
Steroids 
Steroids 
Steroids 
Steroids 
  Steroids 
Steroids, salbutamol 
 ()  Steroids, salbutamol 
() Steroids, salbutamol 
 Steroids IVIG 
 Steroids, IVIG 
Steroids 
Steroids 
  Steroids, IVIG 
   Steroids, salbutamol, IVIG IUD
  No IUD
Steroids 
() Steroids 
   No IUD
() Steroids 
Steroids 
 () Steroids, IVIG 






hydrops/effusions:   hydrops; ()  pericardial effusion; 0  absent; reduced function:  
y termination.diac Aes W
tricul
5 Bea








bsent;odies and noncardiac NLE.
R
m
t
w
W
n
f
r
e
a
p
o
0
t
(
D
D
a
e
a
f
c
c
t
p
A
d
d
h
a
e
n
c
c
1
R
w
H
a
t
a
a
l
C
c
a
w
a
a
c
s
f
a
a
6
M
L
a
l
t
s
o
m
R
o
o
a
l
h
a
e
c
a
5
e
r
c
2782 Jaeggi et al. JACC Vol. 55, No. 24, 2010
Fetal Heart Block and Maternal Antibodies June 15, 2010:2778–84ole of antibody titres on the development of NLE. All
others of children with cardiac involvement had moderate
o high anti-Ro antibody levels (50 U/ml) as compared
ith only 44% of mothers of healthy infants (p  0.0001).
hen we examined only the prospectively followed preg-
ancies, the event rate of CAVB was 5% (3 of 59 cases) for
etuses with exposure to anti-Ro levels 50 U/ml (odds
atio [OR]: 7.8; range 0.4 to 159) and 0% for those
xposed to lower Ro-titres. Conversely, infants of anti-La
ntibody-negative mothers were the least likely to have
ost-natal features of noncardiac NLE, with an event rate
f 19% (13 of 69 cases) and an OR of 0.34 (range 0.13 to
.72). In contrast, 57% of infants with pre-natal exposure
o anti-La levels 100 U/ml had noncardiac NLE
OR: 4.7).
iscussion
espite the consistent finding that only a small minority of
ntibody-exposed fetuses will eventually have clinically rel-
vant cardiac complications, there is the consensus that
nti-Ro/La antibodies are relevant markers of an increased
etal CAVB risk and, therefore, that pregnant women
arrying these antibodies should undergo serial fetal echo-
ardiography beginning in mid-gestation (18–20). Never-
heless, indiscriminate screening of all antibody-positive
regnant women is probably neither practical nor justified.
s confirmed in this study, most cases of cardiac NLE are
etected in asymptomatic women without connective tissue
isease (85%) and without a history of a previous child with
eart block (98%). Because the search for Ro- and La-
ntibodies is not integrated in pregnancy screening, serial
chocardiography of “at risk” pregnancies will, therefore,
ot detect the majority of the fetuses destined to have
ardiac disease before its development.
Furthermore, autoantibodies are relatively common in
hildbearing women. In an earlier prospective study on
5,114 unselected pregnant women in Ontario, we found
o and La antibodies in 2.5% of maternal sera at around 16
eeks of gestation (E. Silverman, L. Hornberger, R.M.
amilton, unpublished data, July 2002). In our catchment
Antibody Profiles of 111 Children With (Yes) orTable 3 Antibody Profiles of 111 Children W
Noncardiac Neonatal Lupus Syndromes
Examined infants without cardiac NLE 30/
Plasma anti-Ro level measurements
Low anti-Ro, 8–49 U/ml
Moderate anti-Ro, 50–99 U/ml
High anti-Ro,100 U/ml
Plasma anti-La level measurements
Negative anti-La,8 U/ml
Low anti-La, 8–49 U/ml
Moderate anti-La, 50–99 U/ml
High anti-La,100 U/ml
NLE  neonatal lupus erythematosus.rea, there are approximately 80,000 live births per year. If phe cardiac NLE risk of the estimated 2,000 anti-Ro/La
ntibody-positive mothers is 1%, as suggested by different
uthors (14–17), then we would expect the referral of at
east 20 fetuses/neonates per year with antibody-associated
AVB in our area. Yet, we regularly encounter 4 or 5 new
ases per year, which is similar to the estimation 4 decades
go that about 1 of every 20,000 live births results in a baby
ith CAVB (24). Given that the average risk of an
ntibody-positive woman for fetal CAVB is perhaps only
bout 0.2%, serial fetal echocardiography appears not indi-
ated for many antibody-positive woman. The aim of this
tudy was therefore to identify a more predictive risk profile
or the development of cardiac NLE, using commercially
vailable measurements of anti-Ro and anti-La antibodies.
Previous studies have shown that all cases of cardiac NLE
re associated with antibodies to at least 1 of the 52- and
0-kD Ro-particles and/or to the 48-kD La-protein (8,9).
ore recently, the response to peptides within the Ro- and
a-proteins has also been examined (9,25,26). While this
pproach has provided new insights into the reasons for the
ow prevalence of cardiac NLE, it has little clinical utility as
hese assays are available in research facilities only. In this
tudy, using commercially available ELISA, we found not
nly that the risk of NLE significantly correlated with
aternal antibody-levels but also demonstrated a cutoff
o-titre, below which we did not observe the development
f cardiac NLE. Antibody-related cardiac complications
ccurred exclusively when a fetus was exposed to anti-Ro
ntibody levels 50 U/ml, irrespective of anti-La antibody
evels. Nearly 60% of serially screened mothers in this study
ad Ro-titres50 U/ml with, in hindsight, no risk of major
ntibody-related cardiac complications.
Although high levels of anti-Ro antibodies appear nec-
ssary, they are not sufficient to explain the development of
ardiac NLE because the majority of women with high
nti-Ro levels have normal pregnancy outcomes. In 5% (3 of
9) of all prospectively screened pregnancies in this study,
xposure to moderate or high anti-Ro antibody levels
esulted in a child with CAVB. Of mothers with a previous
hild with CAVB, the recurrence rate was 11% (1 of 9
out (No) Noncardiac NLEes) or Without (No) Noncardiac NLE
No p Value
7%) 81/111 (73%)
00%) 78 (96%)
0%) 44 (56%) NS
%) 2 (3%) NS
3%) 32 (41%) NS
00%) 78 (96%)
3%) 56 (72%) 0.01
0% 7 (9%) NS
%) 4 (4%) NS
3%) 11 (14%) 0.003Withith (Y
Yes
111 (2
30 (1
18 (6
2 (7
10 (3
30 (1
13 (4
3 (1
1 (3
13 (4regnancies), which is consistent with previous reports
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June 15, 2010:2778–84 Fetal Heart Block and Maternal Antibodies12,14). All women with a previously affected child in this
tudy also had high anti-Ro antibody levels 100 U/ml,
hich may be part of the increased recurrence risk. If
ymptomatic fetuses were also exposed to high La-antibody
evels, however, they appeared to be less severely affected as
one had concomitant myocardial inflammation and EFE
s compared with 38% of fetuses with exposure only to high
nti-Ro levels. The importance of a high anti-La antibody
evel as a marker of a more benign disease pattern needs to
e further addressed in a large prospective study. Finally,
igh-titre anti-La antibody exposure increased the child’s
isk of antibody-mediated noncardiac abnormalities devel-
ping after birth, although these antibodies are probably not
ausal because only 60% of mothers of affected infants had
nti-La antibodies. This association is consistent with
revious studies, including our own, which showed that in
hildren with NLE, high-titre anti-La antibodies were
ore likely to be associated with cutaneous NLE (9,27,28).
The finding of a strong association between anti-Ro
ntibody levels and cardiac NLE supports the hypothesis
hat lowering or eliminating autoantibodies may prevent
uch complications. Some investigators have used plasma-
heresis to eliminate the harmful antibodies in high-risk
regnancies. However, despite the demonstration that plas-
apheresis can decrease anti-Ro antibody levels, this ther-
py was associated with a 7% to 14% rate of CAVB in the
argest reported studies (29,30). More recently, it has been
uggested that the repeated maternal administration of
VIG could prevent tissue damage by decreasing the trans-
lacental passage and by increasing the catabolism of the
aternal anti-Ro antibodies, as well as by modulating
nhibitory signaling on macrophages with consequent re-
uction of inflammation and fibrosis. Although in a murine
odel the administration of IVIG inhibited the transfer of
utoantibodies across the placenta and their subsequent
eposition in the fetal heart (31), a small study in humans
howed that, in 2 of 8 offspring, CAVB or cutaneous NLE
till developed (32). A larger prospective study of 3-weekly
aternal administration of IVIG between 12 and 24 gesta-
ional weeks to prevent cardiac NLE is under way.
tudy limitations. The cutoff levels used in this study are
nly valid for the commercially available ELISA kit used in
his study. The method is highly sensitive and quantitative
o recognize Ro 60-kDa and Ro 52-kDa particles but does
ot distinguish among these specificities.
onclusions
n summary, our study supports the concept that the
evelopment of immune-mediated CAVB and EFE is
ikely linked to the fetal exposure to high titres of anti-Ro
ntibodies, whereas the presence of anti-La antibodies may
ot be required. However, our study does not provide direct
vidence that anti-Ro antibodies are the pathogenic anti-
odies but, rather, just demonstrates association. We have
gain shown that most mothers who have a pregnancyomplicated by significant fetal cardiac involvement are not
dentified before the pregnancy because they do not a have
onnective tissue disease and thus are not referred for
rospective fetal evaluation. Consequently, to improve the
ield of early detection before CAVB, we agree with a
revious suggestion that a successful program to prevent
evere cardiac complications would require the screening for
nti-Ro antibodies of all pregnant women irrespective of
heir symptoms or clinical status (33).
Based on our experience, we suggest that the measure-
ent of anti-Ro antibody levels should be performed rather
han simply test for their presence and that fetal echocar-
iography should be reserved for pregnant women with high
evels. However, individual risk assessment based on anti-
ody titres may help alleviate parental anxiety of having a
hild at risk of an irreversible cardiac condition when
nti-Ro antibody-levels are low. The utility of this approach
eeds confirmation in a large prospective cohort study.
eprint requests and correspondence: Dr. Edgar Jaeggi, The
ospital for Sick Children, 555 University Avenue, Toronto,
ntario M5G 1X8, Canada. E-mail: edgar.jaeggi@sickkids.ca.
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